Berinert, lyophilizate for IV application containing 500 IU C1-INH to be reconstituted with 10 mL water for injection
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Hereditary Angioedema Types I and II
Conditions
Hereditary Angioedema Types I and II
Trial Timeline
Nov 1, 2011 → Oct 1, 2014
NCT ID
NCT01467947About Berinert, lyophilizate for IV application containing 500 IU C1-INH to be reconstituted with 10 mL water for injection
Berinert, lyophilizate for IV application containing 500 IU C1-INH to be reconstituted with 10 mL water for injection is a approved stage product being developed by CSL for Hereditary Angioedema Types I and II. The current trial status is completed. This product is registered under clinical trial identifier NCT01467947. Target conditions include Hereditary Angioedema Types I and II.
What happened to similar drugs?
1 of 20 similar drugs in Hereditary Angioedema Types I and II were approved
Approved (1) Terminated (0) Active (19)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01467947 | Approved | Completed |
Competing Products
20 competing products in Hereditary Angioedema Types I and II
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KVD900 | KalVista Pharmaceuticals | Phase 2 | 29 |
| KVD824 + Placebo to KVD824 | KalVista Pharmaceuticals | Phase 1 | 23 |
| KVD900 600 mg + KVD900 300 mg | KalVista Pharmaceuticals | Phase 3 | 38 |
| Sebetralstat | KalVista Pharmaceuticals | Pre-clinical | 20 |
| KVD900 + Placebo to KVD900 | KalVista Pharmaceuticals | Phase 1 | 23 |
| Sebetralstat | KalVista Pharmaceuticals | Pre-clinical | 24 |
| Placebo + KVD900 600 mg + KVD900 300 mg | KalVista Pharmaceuticals | Phase 3 | 34 |
| KVD824 Prototype 1 modified-release tablet + KVD824 Prototype 2 modified-release tablet + KVD824 Immediate-Release Capsule + Placebo to KVD824 Prototype 1 + KVD824 Prototype 3 modified-release tablet | KalVista Pharmaceuticals | Phase 1 | 23 |
| KVD900 150 mg + KVD900 300 mg + KVD900 600 mg | KalVista Pharmaceuticals | Phase 3 | 34 |
| KVD824 + Placebo to KVD824 | KalVista Pharmaceuticals | Phase 2 | 21 |
| KVD900 600 mg + Drug: KVD900 300 mg | KalVista Pharmaceuticals | Phase 3 | 38 |
| Deferasirox FCT | Novartis | Phase 2 | 27 |
| Canakinumab + Placebo | Novartis | Phase 3 | 40 |
| Ilaris | Novartis | Pre-clinical | 33 |
| Standard of Care for Haemophilia A | Roche | Pre-clinical | 26 |
| Emicizumab | Roche | Phase 3 | 40 |
| Tafamidis | Pfizer | Pre-clinical | 26 |
| tafamidis | Pfizer | Pre-clinical | 26 |
| Nitisinone | Swedish Orphan Biovitrum | Pre-clinical | 26 |
| Nitisinone | Swedish Orphan Biovitrum | Phase 1 | 29 |